Shots:
Novartis has reported data from the biomarker cohort of the P-I/II (FORTITUDE) study assessing delpacibart braxlosiran (2mg/kg, Q6W) vs PBO in 90 pts (16-70yrs.) with facioscapulohumeral muscular dystrophy (FSHD)
Trial met its 1 & key 2EPs, showing reductions in KHDC1L (cDUX) & creatine kinase biomarker levels, which indicates potent target engagement & decrease in…
Shots
Cross-industry lessons from technology, design thinking, and startups can reshape drug development by encouraging faster iteration, disciplined decision-making, and a stronger focus on real patient needs, unlocking innovations that traditional biotech models may overlook.
Clinical experience and thoughtful engagement with the U.S. Food and Drug Administration highlight the importance of patient insights, transparent…
Shots:
NetraMark and Worldwide Clinical Trials have entered into a global agreement to utilize NetraMark’s NetraAI platform to advance clinical trial design
As per the deal, NetraAI will initially support P-II neuroscience & oncology trials, plus select P-III studies conducted by Worldwide, with broader access extended to Worldwide’s sponsors across all therapeutic areas & trial…

